Curcumin inhibits WT1 gene expression in human leukemic K562 cells

Aim: Wilms' tumor1 (WT1) gene is highly expressed in leukemic blast cells of myeloid and lymphoid origin. Thus, WT1 mRNA and protein serve as promising tumor markers for the detection of leukemia and monitoring of disease progression. The purpose of this study was to investigate the modulating...

Full description

Saved in:
Bibliographic Details
Main Authors: Songyot Anuchapreeda, Pattra Thanarattanakorn, Somjai Sittipreechacharn, Prasit Chanarat, Pornngarm Limtrakul
Format: Journal
Published: 2018
Subjects:
Online Access:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33644829130&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/61889
Tags: Add Tag
No Tags, Be the first to tag this record!
Institution: Chiang Mai University
id th-cmuir.6653943832-61889
record_format dspace
spelling th-cmuir.6653943832-618892018-09-11T09:01:43Z Curcumin inhibits WT1 gene expression in human leukemic K562 cells Songyot Anuchapreeda Pattra Thanarattanakorn Somjai Sittipreechacharn Prasit Chanarat Pornngarm Limtrakul Medicine Pharmacology, Toxicology and Pharmaceutics Aim: Wilms' tumor1 (WT1) gene is highly expressed in leukemic blast cells of myeloid and lymphoid origin. Thus, WT1 mRNA and protein serve as promising tumor markers for the detection of leukemia and monitoring of disease progression. The purpose of this study was to investigate the modulating effects of curcumin on WT1 gene expression in the human leukemic cell line K562. Methods: The cytotoxicity of curcumin on the K562 cell line was evaluated by using 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. The K562 cell line was treated with a non-cytotoxic dose of curcumin (5,10, or 15 μmol/L) for 13 d. The expression levels of WT1 protein and WT1 mRNA were assessed by Western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Results: Curcumin had a cytotoxic effect on K562 leukemic cells with an inhibitory concentration at 50% (IC50) of approximately 20 μg/mL (54.3 μmol/L). Non-cytotoxic doses of curcumin, at concentrations of 5,10, and 15 μmol/L for 2 d, decreased the level of WT1 protein and WT1 mRNA in the K562 cell line in a dose-dependent manner. Similarly, curcumin at a concentration of 10 μmol/L significantly decreased the level of WT1 protein and mRNA in a time-dependent manner. Conclusion: The inhibitory effects of curcumin are associated with a decrease in the levels of both WT1 protein and WT1 mRNA. The current study provides a molecular basis for future clinical trials in leukemic patients. Thus, curcumin could be a promising chemotherapeutic agent for human leukemia. ©2006 CPS and SIMM. 2018-09-11T09:00:47Z 2018-09-11T09:00:47Z 2006-03-01 Journal 17457254 16714083 2-s2.0-33644829130 10.1111/j.1745-7254.2006.00291.x https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33644829130&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/61889
institution Chiang Mai University
building Chiang Mai University Library
country Thailand
collection CMU Intellectual Repository
topic Medicine
Pharmacology, Toxicology and Pharmaceutics
spellingShingle Medicine
Pharmacology, Toxicology and Pharmaceutics
Songyot Anuchapreeda
Pattra Thanarattanakorn
Somjai Sittipreechacharn
Prasit Chanarat
Pornngarm Limtrakul
Curcumin inhibits WT1 gene expression in human leukemic K562 cells
description Aim: Wilms' tumor1 (WT1) gene is highly expressed in leukemic blast cells of myeloid and lymphoid origin. Thus, WT1 mRNA and protein serve as promising tumor markers for the detection of leukemia and monitoring of disease progression. The purpose of this study was to investigate the modulating effects of curcumin on WT1 gene expression in the human leukemic cell line K562. Methods: The cytotoxicity of curcumin on the K562 cell line was evaluated by using 3-(4,5-dimethyl-2 thiazoyl)-2,5-diphenyl-tetrazolium bromide (MTT) assay. The K562 cell line was treated with a non-cytotoxic dose of curcumin (5,10, or 15 μmol/L) for 13 d. The expression levels of WT1 protein and WT1 mRNA were assessed by Western blot analysis and reverse transcription-polymerase chain reaction (RT-PCR), respectively. Results: Curcumin had a cytotoxic effect on K562 leukemic cells with an inhibitory concentration at 50% (IC50) of approximately 20 μg/mL (54.3 μmol/L). Non-cytotoxic doses of curcumin, at concentrations of 5,10, and 15 μmol/L for 2 d, decreased the level of WT1 protein and WT1 mRNA in the K562 cell line in a dose-dependent manner. Similarly, curcumin at a concentration of 10 μmol/L significantly decreased the level of WT1 protein and mRNA in a time-dependent manner. Conclusion: The inhibitory effects of curcumin are associated with a decrease in the levels of both WT1 protein and WT1 mRNA. The current study provides a molecular basis for future clinical trials in leukemic patients. Thus, curcumin could be a promising chemotherapeutic agent for human leukemia. ©2006 CPS and SIMM.
format Journal
author Songyot Anuchapreeda
Pattra Thanarattanakorn
Somjai Sittipreechacharn
Prasit Chanarat
Pornngarm Limtrakul
author_facet Songyot Anuchapreeda
Pattra Thanarattanakorn
Somjai Sittipreechacharn
Prasit Chanarat
Pornngarm Limtrakul
author_sort Songyot Anuchapreeda
title Curcumin inhibits WT1 gene expression in human leukemic K562 cells
title_short Curcumin inhibits WT1 gene expression in human leukemic K562 cells
title_full Curcumin inhibits WT1 gene expression in human leukemic K562 cells
title_fullStr Curcumin inhibits WT1 gene expression in human leukemic K562 cells
title_full_unstemmed Curcumin inhibits WT1 gene expression in human leukemic K562 cells
title_sort curcumin inhibits wt1 gene expression in human leukemic k562 cells
publishDate 2018
url https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=33644829130&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/61889
_version_ 1681425704818835456